Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study

Circulation

Volumn 119, Issue 18, 2009, Pages 2471-2479

  Iraqi, Wafae ^a,b,c   Rossignol, Patrick ^a,b,c   Angioi, Michael ^b,c,g   Fay, Renaud ^a,b,c   Nuée, Josette ^a,b,c   Ketelslegers, Jean Marie ^d   Vincent, John ^e   Pitt, Bertram ^f   Zannad, Faiez ^a,b,c,g  

^a Ctr Hospitalier Univ de Nancy   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e PFIZER INC   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Biological markers; Collagen; Extracellular matrix; Heart failure; Myocardial infarction

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BRAIN NATRIURETIC PEPTIDE; EPLERENONE; NEUROHORMONE; PLACEBO; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; ALDOSTERONE ANTAGONIST; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DRUG DERIVATIVE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH;

AGED; ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; COLLAGEN TYPE I; COLLAGEN TYPE III; DEATH, SUDDEN, CARDIAC; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SPIRONOLACTONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 66549112420     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.809194     Document Type: Article

References (30)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
2. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators Circulation. 2000;102:2700-2706.
3. Quilliot D, Alla F, Bohme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O, Zannad F. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Land). 2005;29: 1321-1328.
4. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-262.
5. Jugdutt BI. Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction. J Card Fail. 2006; 12:73-76.
6. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79-87.
7. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation. 1997;96:2488-2492.
8. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.
9. Jensen LT, Horslev-Petersen K, Toft P, Bentsen KD, Grande P, Simonsen EE, Lorenzen I. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation. 1990;81: 52-57.
10. Uusimaa P, Risteli J, Niemela M, Lumme J, Ikaheimo M, Jounela A, Peuhkurinen K. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation. 1997;96:2565-2572.
11. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation. 2000; 101:1527-1532.
12. Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol. 1995;76:869-873.
13. Takino T, Nakamura M, Hiramori K. Circulating levels of carboxy-terminal propeptide of type I procollagen and left ventricular remodeling after myocardial infarction. Cardiology. 1999;91:81-86.
14. Poulsen SH, Host NB, Egstrup K. Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction. Cardiology. 2001;96:45-50.
15. Radovan J, Vaclav P, Petr W, Jan C, Michal A, Richard P, Martina P. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem. 2006;293:71-78.
16. Magga J, Puhakka M, Hietakorpi S, Punnonen K, Uusimaa P, Risteli J, Vuolteenaho O, Ruskoaho H, Peuhkurinen K. Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction. J Appl Physiol. 2004;96:1306-1311.
17. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281-1292.
18. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325-338.
19. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
20. Cerisano G, Pucci PD, Sulla A, Tommasi M, Raspanti S, Santoro GM, Antoniucci D. Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodeling after reperfused acute myocardial infarction. Am J Cardiol. 2007;99:651-656.
21. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail. 2002;4:439-434.
22. Murakami T, Kusachi S, Murakami M, Sano I, Uesugi T, Hirami R, Kajiyama A, Kondo J, Tsuji T. Time-dependent changes of serum carboxy-terminal peptide of type I procollagen and carboxy-terminal telopeptide of type I collagen concentrations in patients with acute myocardial infarction after successful reperfusion: correlation with left ventricular volume indices. Clin Chem. 1998;44:2453-2461.
23. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail. 2008; 14:467-474.
24. Radauceanu A, Moulin F, Djaballah W, Marie PY, Alia F, Dousset B, Virion JM, Capiaumont J, Karcher G, Aliot E, Zannad F. Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. Eur J Heart Fail. 2007;9:370-376.
25. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28:1863-1867.
26. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:753-755.
27. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
28. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
29. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
30. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem. 2005;338:294-298.